Karyopharm Therapeutics Receives Nasdaq Delisting Notice Following Chapter 11 Filing

Nasdaq notified Karyopharm Therapeutics on November 4, 2026, that it would delist the company’s securities following its Chapter 11 filing; Karyopharm will not appeal. Trading is scheduled to be suspended at the market open on November 11, after which the shares are expected to trade over the counter as KPTIQ. The bankruptcy plan provides for no distribution to common or preferred stockholders, and the company expects its existing equity securities to have no value.